NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDERIDE LA 120/50 is a fixed-dose combination of propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release capsule form. It is indicated for the management of hypertension in patients who require dual antihypertensive therapy. The combination works by reducing cardiac output and peripheral vascular resistance while promoting sodium and water excretion.
LOE Approaching
Declining market relevance with LOE approaching signals consolidation or portfolio rationalization; team size likely minimal to maintenance-only.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INDERIDE LA offers limited career growth due to its legacy status and approaching loss of exclusivity. Roles are primarily focused on maintaining existing market share, managing generic transition, and regulatory compliance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on INDERIDE LA 120/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.